Trubion Pharmaceuticals, Inc. (TRBN) is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of protein therapeutic medicines to treat autoimmune diseases and cancer. The company utilizes proprietary technology to develop drugs that are safer and more effective than currently available therapies.
Trubion's current product candidates are novel single-chain polypeptide proteins which are called small modular immunopharmaceutical (SMIP). These candidates are designed using the company's custom drug assembly technology. These product candidates bind to specific antigen targets on a cell's surface that have been clinically validated as important in disease management either by existing products or by potential products in clinical trials. Trubion's product candidates may offer the potential for safer and more effective therapies than existing or other potential products. In December 2005 Trubion entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including its lead product candidate, TRU-015. To date, none of its product candidates has been approved for marketing and sale and the company has not received any product revenue.
Trubion Pharmaceuticals, Inc. was originally formed in 1999 in the state of Washington as a limited liability company and reincorporated in October 2002 in the state of Delaware. In September 2003 the company changed its name to Trubion Pharmaceuticals, Inc. Trubion went public in October 2006 and is headquartered in Seattle, WA.
The following table summarizes the pipeline information of the company.
Phase IIb, preliminary results presented
Systemic Lupus Erythematosus (SLE)
IND filed in 4Q07